Compare MNPR & NGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MNPR | NGS |
|---|---|---|
| Founded | 2014 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Oilfield Services/Equipment |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 587.4M | 473.6M |
| IPO Year | 2019 | 2006 |
| Metric | MNPR | NGS |
|---|---|---|
| Price | $70.28 | $28.79 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 3 |
| Target Price | ★ $130.17 | $53.67 |
| AVG Volume (30 Days) | ★ 127.0K | 93.3K |
| Earning Date | 11-12-2026 | 11-09-2026 |
| Dividend Yield | N/A | ★ 2.22% |
| EPS Growth | ★ 54.99 | 14.60 |
| EPS | N/A | ★ 1.26 |
| Revenue | N/A | ★ $172,315,000.00 |
| Revenue This Year | N/A | $27.81 |
| Revenue Next Year | N/A | $15.71 |
| P/E Ratio | ★ N/A | $22.93 |
| Revenue Growth | N/A | ★ 9.94 |
| 52 Week Low | $50.07 | $26.39 |
| 52 Week High | $124.82 | $44.61 |
| Indicator | MNPR | NGS |
|---|---|---|
| Relative Strength Index (RSI) | 42.77 | 43.18 |
| Support Level | $66.88 | $26.39 |
| Resistance Level | $75.33 | $33.75 |
| Average True Range (ATR) | 4.74 | 1.61 |
| MACD | 0.73 | 0.04 |
| Stochastic Oscillator | 51.81 | 36.76 |
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.
Natural Gas Services Group Inc provides natural gas compression equipment and services to the energy industry. The company manufactures, fabricates, rents, sells, and maintains natural gas compressors and flare systems for oil and natural gas production and plant facilities. Its operating units include Rental, Sales, and Aftermarket services. It operates in one reporting segment. The company generates the majority of its revenue by renting out low- to medium-horsepower compression equipment to natural gas production companies in unconventional oil and gas regions of the United States.